ARRIGE association launched: the Founding Board

The ARRIGE association was registered in France on 4 December 2018 with the name Association for Responsible Research and Innovation in Genome Editing (ARRIGE) as a non-for-profit association.

The official address of ARRIGE is at the Center for Interdisciplinary Research (CRI), 8 rue Charles V, 75005 Paris, France.

These are the ARRIGE bylaws (in French). A copy in English will be made available shortly.

The objectives of ARRIGE are:

    1. to promote a global governance of genome editing through a comprehensive setting for all stakeholders, including academics, researchers, clinicians, public institutions, private companies, patient organizations and other non-governmental organizations, regulators, citizens, communication media, governmental agencies and decision makers
    2. to push forward the scientific, ethical, social, legal and political reflection in the field of genome editing
    3. to foster the development of genome editing technologies within a safe and ethical framework for individuals and for our societies
    4. the dissemination of reliable information regarding genome-editing technology for experts (all fields included), politicians and citizens throughout the world.

The Founding Board of ARRIGE is formed by:

President: Lluís Montoliu (Spain)
Vice-President: Hervé Chneiweiss (France)
General Secretary: François Hirsch (France)
Deputy General Secretary: Christine Lemaitre (France)
Treasurer: Cyril Sarrauste de Menthière (France)
Deputy Treasurer: Jennifer Merchant (France)
Legal Advisor: Marion Abecassis (France)
Board member: Bernard Baertschi (Switzerland)

Author: Lluis

Lluis Montoliu (Barcelona, Spain, 1963) graduated in Biological Sciences (1986) and obtained his PhD in Molecular Genetics (1990) at the University of Barcelona. Research Scientist of the Spanish National Research Council (CSIC) at the National Centre for Biotechnology (CNB), in Madrid (Spain) since 1997, after two postdoctoral periods in Heidelberg (German Cancer Research Center, 1991-1995) and Barcelona (Autonomous University of Barcelona, 1995-96). Since 2007 appointed researcher at the Spanish Research Initiative on Rare Diseases (CIBERER-ISCIII) where he is now serving at its Steering Committee. Since 1998 he is Honorary Professor at the Autonomous University of Madrid and, since 2007, Director of the Spanish node of the European Mouse Mutant Archive (EMMA/INFRAFRONTIER) Spanish node. Including his PhD, from 1986, where he worked in plant molecular genetics, in maize, he has been always working on the genetic modification of organisms (GMOs). Since 1991 he has been working in several scientific projects within the field of animal transgenesis. At the CNB he leads a research team interested in basic science, to understand the mechanisms controlling gene expression and organization in mammalian genomes, and in applied science, generating animal models for the study of human rare diseases, such as albinism. He has pioneered the use of in vivo genome-editing CRISPR approaches in Spain for the functional analysis of the non-coding genome. He is the current President of the European Society for Pigment Cell Research (ESPCR) and serves at the boards of additional societies (IFPCS, IMGS, ACB). In 2006, he founded the International Society for Transgenic Technologies (ISTT) for which he has served as President since inception to 2014. He is a member of the CSIC Ethics Committee and the Ethics Panel of ERC in Brussels. In addition to research he is also interested in bioethics, education and popular science.

Leave a Reply

Your email address will not be published. Required fields are marked *